We describe a neonate with isotretinoin embryopathy and an incidental finding of congenital neuroblastoma. Diffuse liver metastases led to the decision to provide oncologic therapy followed by tumor resection. Despite the possible need for chronic care related to the comorbidities of the isotretinoin embryopathy and oncologic management, the patient remains disease-free. Because of the uncertain etiology of neuroblastoma, it remains unclear whether exposure to isotretinoin during embryogenesis and fetal development had an oncogenic effect on this patient.
*Texas Children’s Cancer Center
†Department of Pathology, Baylor College of Medicine, Houston, TX
C.L. has Royalties from Cell Medica. P.Z. has an Independent Medical Grant from EMD Serono Inc. The remaining authors declare no conflict of interest.
Reprints: Shiley Aguilar, MSN, RN, FNP-C, Texas Children’s Cancer Center, Baylor College of Medicine, 6701 Fannin St., Suite 1500, Houston, TX 77030 (e-mail: firstname.lastname@example.org).
Received July 11, 2012
Accepted February 26, 2013